You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 騰盛博藥漲6% 本週累漲超70% 乙肝藥物SIRNA臨牀II期試驗初步結果展現較好療效
格隆匯 11-18 10:49
格隆匯11月18日丨騰盛博藥連續第四日上漲,今日盤中漲6.78%,報37.8港元,總市值272億港元,本週累漲超70%。2021 年11 月15 日的美國肝病協會年會(AASLD)上,騰盛博藥(02137)的合作伙伴Vir Biotechnology公佈了乙肝siRNA藥物BRII-835 (VIR-2218)聯合PEGIFN-α聯用的臨牀II期試驗初步結果,展現出了較好的療效。另外,中金此前發佈報吿,認為騰盛博藥將通過新冠中和抗體實現商業化轉變,首予其“跑贏行業”評級。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account